Background
The Endeavor TM stent (Medtronic Corp., USA) represents a second-generation drug-eluting stent (DES). The combination of a nickel–chromium–cobalt alloy, a phosphorylcholine polymer and zotarolimus makes this stent somewhat unique. We aimed to evaluate its safety and efficacy in daily practice.
Methods
Between September 2005 and September 2007, we included all patients of our clinic who had received at least one Endeavor TM stent during coronary angioplasty in a prospective registry containing clinical as well as procedural data. During follow-up, patients have been contacted after 12 and 24–36 months using a written questionnaire or by telephone contact to evaluate clinical events. Primary endpoints were target lesion revascularization (TLR) and the combined endpoint of death, myocardial infarction (MI) and target vessel revascularization (TVR). Secondary endpoints were stent thrombosis rate, duration of dual antiplatelet therapy (DAPT) and bleeding events.
Methods
Between September 2005 and September 2007, we included all patients of our clinic who had received at least one Endeavor TM stent during coronary angioplasty in a prospective registry containing clinical as well as procedural data. During follow-up, patients have been contacted after 12 and 24–36 months using a written questionnaire or by telephone contact to evaluate clinical events. Primary endpoints were target lesion revascularization (TLR) and the combined endpoint of death, myocardial infarction (MI) and target vessel revascularization (TVR). Secondary endpoints were stent thrombosis rate, duration of dual antiplatelet therapy (DAPT) and bleeding events.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
